Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for ...

Doctors caution that while Ozempic can help manage diabetes and obesity under medical supervision, misuse as a weight-loss ...

Ozempic has officially arrived in India at a comparatively affordable price, sparking buzz among diabetes and weight loss ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Investigation ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently completed a study titled ‘Efficacy ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...